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Most cell-surface receptors for cytokines and growth
factors signal as dimers, but it is unclear whether re-
modeling receptor dimer topology is a viable strat-
egy to ‘‘tune’’ signaling output. We utilized diabodies
(DA) as surrogate ligands in a prototypical dimeric
receptor-ligand system, the cytokine Erythropoietin
(EPO) and its receptor (EpoR), to dimerize EpoR
ectodomains in non-native architectures. Diabody-
induced signaling amplitudes varied from full to min-
imal agonism, and structures of these DA/EpoR
complexes differed in EpoR dimer orientation and
proximity. Diabodies also elicited biased or differen-
tial activation of signaling pathways and gene
expression profiles compared to EPO. Non-signaling
diabodies inhibited proliferation of erythroid pre-
cursors from patients with a myeloproliferative
neoplasm due to a constitutively active JAK2V617F
mutation. Thus, intracellular oncogenic mutations
causing ligand-independent receptor activation can
be counteracted by extracellular ligands that re-
orient receptors into inactive dimer topologies. This
approach has broad applications for tuning signaling
output for many dimeric receptor systems.INTRODUCTION
Receptor dimerization is a universal mechanism to initiate signal
transduction and is utilized by many growth factors such as cy-
tokines and ligands for receptor tyrosine kinases (RTK), among
others (Klemm et al., 1998; Stroud and Wells, 2004; Ullrich and1196 Cell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc.Schlessinger, 1990; Wang et al., 2009; Wells and de Vos,
1993). Cytokines are a large class of secreted glycoproteins
that contribute to regulating the fate and function of most cell
types (Bazan, 1990; Liao et al., 2011; Wang et al., 2009). Cyto-
kines bind to the extracellular domains (ECD) of their cell-surface
receptors, forming signaling complexes with receptor homo- or
hetero-dimers. Although the dimer is the fundamental signaling
unit, cytokine receptor-ligand complexes can form in higher-
order assemblies (Boulanger et al., 2003; Hansen et al., 2008).
In some cases, cytokine receptors may be pre-associated on
the cell surface in an inactive state, with the cytokines re-orient-
ing the receptor dimers into an active state (Brooks et al., 2014;
Constantinescu et al., 2001; Gent et al., 2002; Livnah et al.,
1999). Cytokines such as erythropoietin (EPO) and growth
hormone (GH) homodimerize two identical receptor subunits
(Constantinescu et al., 1999; Wells and de Vos, 1993), while
other cytokines, such as tnterleukin-2, heterodimerize a shared
receptor (common gamma chain) with a cytokine-specific sub-
unit to initiate signaling (Liao et al., 2011; Wang et al., 2009).
Cytokine receptor dimerization principally results in activation
of intracellular, non-covalently associated Janus kinases
(JAKs), which then activate the STAT pathway to modulate
gene expression and ultimately determine cell fate (Ihle et al.,
1995; O’Shea and Paul, 2010).
Structures of cytokine-receptor ECD complexes from different
systems have revealed a diverse range of molecular archi-
tectures and receptor dimer topologies that are compatible
with signaling (Boulanger et al., 2003; de Vos et al., 1992; Hansen
et al., 2008; LaPorte et al., 2008; Livnah et al., 1996; Ring et al.,
2012; Syed et al., 1998; Thomas et al., 2011; Walter et al., 1995;
Wang et al., 2005). This topological diversity is also apparent for
dimeric RTK ECD complexes with their agonist ligands (Kavran
et al., 2014; Lemmon and Schlessinger, 2010). Furthermore,
monoclonal antibodies, engineered ligands, and other agents
that dimerize receptor extracellular domains can have disparate
impacts on signaling, but the topological relationships of these
non-native dimers to those induced by the endogenous ligands
are unknown (Boersma et al., 2011; Harwerth et al., 1992; Jost
et al., 2013; Kai et al., 2008; Li et al., 2013; Mu¨ller-Newen
et al., 2000; Nakano et al., 2009; Zhang et al., 2012a). Prior
studies have shown that cytokine receptor signaling efficiency
can be influenced by extracellular domainmutations or structural
perturbations (Barclay et al., 2010; Liu et al., 2009; Millot et al.,
2004; Rowlinson et al., 2008; Seubert et al., 2003; Staerk et al.,
2011). However, the apparent permissiveness in dimer architec-
ture compatible with signaling raises the following questions: to
what degree does modulation of receptor-ligand dimer geome-
try fine-tune receptor activation (Ballinger and Wells, 1998),
and could such an approach constitute a practical strategy to
control dimeric receptor signaling output? Correlating the struc-
ture of a receptor-ligand complex in different dimerization topol-
ogies to functional properties, including membrane-proximal
and membrane-distal signaling outputs would be informative in
addressing this question.
On one hand, prior studies showing that cytokine-induced
intracellular signaling could be activated through chimeric re-
ceptors containing alternative ECDs demonstrated that con-
straints on dimerization geometries compatible with signaling
were loose to some degree (Heller et al., 2012; Ohashi et al.,
1994; Pattyn et al., 1999; Socolovsky et al., 1998). On the other
hand, a series of studies comparing activation of EpoR by its
natural ligand EPO versus synthetic peptides concluded that
small changes in dimer orientation could modulate signal
strength (Livnah et al., 1996, 1998; Syed et al., 1998). However,
these studies left open the question of whether the observed
signaling efficiency differences were attributable to alternative
dimer topologies or ligand affinity. In one example, it was re-
ported that an EPO agonist peptide (EMP-1) could be converted
into a non-activating, or ‘‘antagonist’’ peptide (EMP-33) through
a chemical modification (Bromination) of the EMP-1 peptide.
Crystal structures of both peptide ligands bound to the extracel-
lular domains of EpoR revealed dimeric complexes (Livnah
et al., 1996, 1998); however, it was noted that the non-signaling
EMP-33/EpoR ectodomain dimer angle differed by an 15
rotation versus the agonist EMP-1/EpoR dimeric complex (Liv-
nah et al., 1998; and Figure S1A). The lack of signal initiation
by the EMP-33 peptide was attributed to this small change in
the EpoR ECD dimer angle.
RESULTS
EPO Receptor Dimerization and Signal Activation
Induced by EMP Peptides
Given the diverse range of dimer topologies evident in agonistic
cytokine-receptor complexes (Wang et al., 2009), that in many
cases exceed 15 angular differences, we revisited the striking
observation seen with the EPO peptide ligands. We explored
the biological activity of these peptides using EpoR reporter cells
we developed that gave us the ability to test EpoR signaling
by receptor phosphorylation but, importantly, also using a
beta-galactosidase complementation system that is a sensitive
reporter of EPO-induced EpoR oligomerization in physiologic
conditions at 37C, which directly informs on early signalingand internalization (Wehrman et al., 2007). First, we synthesized
the EMP-1 and EMP-33 peptides and found that EMP-1 binds
EpoR with a KD of 1 mM, whereas EMP-33 binds EpoR with a
KD of more than 50 mM (Figures S1B and S1C). The low affinity
of EMP-33 prompted us to ask whether its lack of receptor acti-
vation is due to low occupancy of the receptor on the cell. We
measured the actions of both peptides at inducing signaling
and receptor dimerization on cells at a wide range of concentra-
tions. At 10 mMof peptide, only EMP-1 induced dimerization and
phosphorylation of EpoR at levels comparable to those achieved
by EPO stimulation (Figures 1A and 1B). At higher concentrations
of peptide (100 mM), approaching that used for co-crystallization
of both the agonistic and non-signaling dimeric EpoR/peptide
complexes, EMP-33 induced a similar degree of receptor dimer-
ization and phosphorylation of EpoR as EMP-1 and EPO itself
(Figures 1A and 1B). Thus, when EMP-33 is applied at concen-
trations that dimerize EpoR on cells, the dimer geometry of the
EMP-33/EpoR complex is competent to initiate signaling. The
different signaling potencies exhibited by the EPO mimetic pep-
tides appear to be primarily due to their relative EpoR binding
affinities.
EpoR Diabodies Induce Different Degrees of Agonism
Activity
We turned our attention to developing surrogate cytokine ligands
that could induce much larger topological differences in the
EpoR dimer and enable a systematic study relating dimer archi-
tecture to signaling and function. We reasoned that diabodies,
which are covalently linked dimeric antibody VH/VL variable
domain fragments (Fvs) possessing two binding sites, could
dimerize and possibly induce signaling of the EpoR, albeit at
significantly larger inter-dimer distances than induced by EPO.
Additionally, diabodies might be constrained enough to allow
crystallization of their complexes with EpoR so that we can
directly visualize the dimeric topologies (Perisic et al., 1994).
By comparison, whole antibodies have been shown to activate
cytokine receptor signaling in many systems, presumably by
dimerization (Mu¨ller-Newen et al., 2000; Zhang et al., 2012a,
2013). However, the segmental flexibility of intact antibodies
has precluded a structural analysis of intact dimeric agonist
complexes that can be related to the biological activities.
We synthesized genes of four previously reported anti-EpoR
antibodies (Lim et al., 2010) and re-formatted their VH and VL
domains into diabodies (Figure 1C). The four diabodies bound
EpoR with approximately similar affinities (Figure S2) and multi-
merized EpoR with similar efficiency (as measured by EC50),
albeit less efficiently than EPO (Figure 1D). However, they
induced EpoR phosphorylation with very different relative effi-
cacies, ranging from full agonism (DA5) to very weak partial ag-
onism (DA10) (Figure 1E). The four diabodies also exhibited
different extents of STAT5 phosphorylation (Figure 1F), STAT5
transcriptional activity (Figure S3A), Ba/F3 cell proliferation
(Figure 1G), and CFU (colony forming unit)-E colony formation
(Figure 1H). These dramatic differences in diabody-induced
signaling and functional activities persist at saturating ligand
concentrations, so are not attributable to significantly different
relative affinities for EpoR or to a stronger EpoR internalization
induced by the weak agonist diabodies (DA10, DA307, andCell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc. 1197
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Figure 1. EpoR Dimerization and Signaling
Potencies Induced by EMPs and Diabodies
(A and B) Levels of EpoR dimerization (A) and
phosphorylation (B) promoted by EMPs at the
indicated doses. Data (mean ± SD) are from four
independent replicates.
(C) Schematic view of a bivalent diabody molecule.
VH is connected to the VL domain by a short Gly-
linker. EpoR binding sites in the diabody are
highlighted with a yellow circle.
(D and E) Levels of EpoR dimerization (D) and
phosphorylation (E) promoted by diabodies at the
indicated doses. Data (mean ± SD) are from four
independent replicates.
(F) Percentage of pSTAT5 activation induced by
the indicated doses of EPO or the four diabodies in
Ba/F3 EpoR cells. Data (mean ± SD) are from two
independent experiments.
(G) Ba/F3 proliferation in response to EPO or the
four diabodies. Data (mean ± SD) are from two
independent replicates.
(H) Number of CFU-E colonies derived frommouse
bone marrow induced by EPO and the four dia-
bodies. Data (mean ± SD) are from three different
experiments.
See also Figures S1, S2, and S3.DA330) because the internalization closely correlated with their
signaling efficacies (Figure S3B).
EpoR Diabodies Induce Differential Signal Activation
STAT5 is the most prominent STAT protein activated by EPO
(Constantinescu et al., 1999). However additional signaling path-
ways, including other STATs (STAT1 and STAT3), the MAPK
pathway, and the PI3K pathway, are also activated by this cyto-
kine and fine-tune its responses (Constantinescu et al., 1999).
‘‘Biased’’ signal activation is a phenomenon that has been
described forG-protein-coupled receptor (GPCR) ligands,where
one GPCR can differentially activate signaling pathways (e.g.,
beta-arrestin versus G protein), depending on the ligand (Drake
et al., 2008). Thus, we asked whether similar differential signal
activation could be observed in a dimeric single-pass transmem-
brane receptor such as the EPO-EpoR system. We studied
the activation of 78 different signaling molecules (Table S1) by1198 Cell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc.phospho-flow cytometry in the EPO-
responsive cell line UT7-EpoR. EPO and
the diabodies induced the activation
of 33 signaling proteins, including mem-
bers of the STAT family (STAT1, STAT3,
and STAT5), MAP kinase family (MEK and
p38), and PI3K family (Akt, RSK1, and
RPS6) (Figure 2A). We also observed the
upregulation of known EPO-induced tran-
scription factors such asMyc, cFos, IRF1,
and Elk (Figure 2A). In agreement with our
previous results, the signaling potencies
exhibited by the three diabodies ranged
from full agonism for DA5 to partial ago-
nism for DA330 and non-agonism forDA10 (Figure 2A). Interestingly, the diabodies did not activate
all 33 signaling molecules to the same extent (Figure 2B). When
the signal activation levels induced by the three diabodies after
15 min stimulation were normalized to those induced by EPO,
we observed that, although EPO and DA5 induced similar levels
of activation in the majority of the signaling pathways analyzed,
DA5 activated some of them to a lower extent than EPO (Fig-
ure 2B). Among those, STAT1 and STAT3 activation were the
most affected, with DA5 inducing 30% of the STAT1 and 40%
of the STAT3 activation levels induced by EPO (Figure 2B). Inter-
estingly, STAT3 S727 phosphorylation, which requires MAPK
activation (Decker and Kovarik, 2000), was equally induced by
EPO and DA5, which is consistent with the two ligands activating
theMAPKpathway to the sameextent (Figures 2Aand2B). Dose/
response studies in UT7-EpoR cells confirmed these observa-
tions and showed that DA5 activates STAT1 to a lesser extent
than EPO, while still promoting comparable levels of STAT5
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Figure 2. ‘‘Biased’’ Signaling Activation
Induced by the Diabodies
(A) Bubble plot representation of the signaling
pathways activated by EPO and the three dia-
bodies at the indicated times in UT-7-EpoR cells.
The size of the bubble represents the intensity of
the signal activated.
(B) The levels of signal activation induced by the
three diabodies at 15 min of stimulation were
normalized to those induced by EPO and order
based on signaling potency. The red line repre-
sents the EPO signaling activation potency
normalized to 100%. Data (mean ± SD) are from
three independent replicates.
(C) pSTAT1 and pSTAT5 dose-response experi-
ments performed in UT-7-EpoR cells stimulated
with EPO or DA5 for 15 min. Data (mean ± SD) are
from two independent replicates.
(D) Bubble plot representation of genes induced
by EPO and the three diabodies after stimulation of
MEP cells for 2 hr. The size of the bubble repre-
sents the fold of gene induction.
See also Figure S3 and Table S1.activation (Figure 2C). Thus, biased signaling can be induced
through the dimeric EpoR with surrogate ligands.
Next, we studied how different signal activation amplitudes
exhibited by the diabodies at the membrane-proximal level
would impact their membrane-distal gene expression programs.
We carried out RNA sequencing (RNA-seq) studies of EPO-
responsive genes in purified human primary megakaryocyte-
erythroid progenitor (MEP) cells derived from bone marrow
of a normal subject (Figure 2D). Temporally, MEPs are the first
progenitors to robustly express EpoR during hematopoiesis
in humans (Seita et al., 2012). In agreement with the signaling
data, the relative gene-induction potencies exhibited by the
diabodies matched their signaling efficacies (i.e., DA5 >
DA330 > DA10) (Figure 2D). DA5 induced a very similar gene in-
duction profile to EPO but with some differences, with a small
subset of genes (e.g., Pim2 andRN7SK) being differentially regu-
lated by DA5 when compared to EPO.Cell 160, 1196–1208The different EPO-responsive gene in-
duction potencies elicited by the diabod-
ieswere further confirmedbyqPCRexper-
iments in the EPO-responsive cell line
UT7-EpoR. UT-7-EpoR cells were stimu-
lated with saturating doses of EPO or the
three diabodies for 2, 4, and 8 hr, and the
levels of CISH and Pim1 gene expression
were studied (Figure S3C). Here again,
DA5 stimulation led to similar levels of
CISH and Pim1 induction as EPO; DA330
resulted in only 30%–40% induction of
these genes, and DA10 only marginally
inducedCISH andPim1 in these cells (Fig-
ure S3C).When compared to theRNA-seq
experiment performed in MEP cells, DA10
induced a lower level of CISH and Pim1
expression in UT7-EpoR cells. These dif-ferences likely result from the use of different cell types in the
two assays. Overall, our signaling and gene expression data
show that the diabodies exhibit various degrees of differential
signaling properties relative to EPO and to one another.
Alternative EpoR Dimer Orientation and Proximity
Result in Different Degrees of Agonism
To explore the structural basis for the differential signaling acti-
vation exhibited by the diabodies, we expressed and purified
three diabody/EpoR complexes (DA5, DA10, and DA330) from
baculovirus-infected insect cells. All exhibitedmolecular weights
of 97–98 kDa asmeasured bymulti-angle light scattering (MALS)
chromatography, in agreement with a 2:1 complex stoichiometry
(two EpoR bound to one diabody [Figure S4A]). We crystallized
the diabody/EpoR complexes (DA5 [2.6 A˚], DA10 [3.15 A˚], and
DA330 [2.85 A˚]) and determined their structures by molecular
replacement (Figure 3 and Table S2). The diabody subunit, March 12, 2015 ª2015 Elsevier Inc. 1199
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B C D Figure 3. Crystal Structures of DA5, DA10,
and DA330 in Complex with EpoR
(A) Overlay of the three diabody_EpoR complexes.
EpoR binding to DA5 is colored green, EpoR
binding to DA10 is colored red, and EpoR binding
to DA330 is colored purple. The DA330 crystal
lattice appears to contain domain-swapped dia-
bodies as scFv in similar but not identical subunit
relationships.
(B) Diabodies binding footprint on the EpoR sur-
face. Amino acids on EpoR interacting with the
diabodies are colored white. DA5 CDRs are
colored green; DA10 CDRs are colored red, and
DA330 CDRs are colored purple. Vectors con-
necting the VH CDR1 and the VL CDR1 in the dia-
bodies define the binding topology of the three
diabodies_EpoR complexes.
(C and D) Diabodies and EPO binding footprint on
the EpoR surface. Hotspot interactions on EpoR
are colored lime and are shared by the diabodies
and EPO. Diabodies use Y34, R98 (DA5), Y105
(DA10), Y32, and R101 (DA330) to interact with the
amino acids forming the two hotspots on EpoR.
EPO uses similar chemistry with F43 and K45 filling
the two hotspot pockets on EpoR.
(E–H) Crystal structures of DA5 (E), DA10 (F),
DA330 (G), and EPO (H) dimerizing two EpoR are
shown in top (left) and side (right) views. In the side
view representation, EpoR is depicted as surface.
Yellow spheres represent the C-terminal region of
the SD2 EpoR domain.
See also Figures S4, S5, and S6 and Table S2.relationships are clear for the most and least potent diabody
complexes (DA5 and DA10, respectively). For the DA330/EpoR
complex, the crystal appears to contain domain-swapped dia-
bodies as ‘‘back-to-back,’’ single-chain Fvs that pack in similar,
but not identical, subunit relationships as diabodies. The MALS
data show that all of the diabodies are the expected 2:1 com-
plexes in solution.
All three diabodies converge on the protruding ‘‘elbow’’ of
EpoR that also serves as the EPO binding site (Figures 3, S4,
and S5). When the diabody VH/VL modules are aligned, the
EpoR’s ‘‘rotational’’ binding topology is most similar between
DA5 and DA330, with DA10 being markedly different (Figure 3A).
Although DA5 and DA330 both bind horizontally and differ pri-1200 Cell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc.marily in their vertical ‘‘tilt’’ (14), DA10
is orthogonally disposed relative to
the other two (Figure 3B). In a striking
example of chemical mimicry of EPO
binding, the diabody CDR loops use two
patches of basic (Arg98/Arg101 of DA5
and DA330, respectively) and hydropho-
bic (Tyr34/Tyr105/Tyr32 of DA5/DA10/
DA330, respectively) residues in a nearly
identical manner as residues presented
on the EPO helices (Lys45 and Phe48) in
the EPO site I binding interface to engage
the same regions of the EpoR binding site
(Figures 3C and 3D).The overall architectures of the three diabody/EpoR com-
plexes (Figures 3E–3G) are quite distinct from that of the EPO/
EpoR complex, which dimerizes two molecules of EpoR in a
classical Y-fork cytokine-receptor architecture, resulting in close
proximity between the C termini of the membrane-proximal
EpoR ECDs (Figure 3H). In contrast, the diabodies impose
much larger separation between the two EpoR molecules with
distances ranging from 127 A˚ in the case of the DA5/EpoR
(full agonist) complex to 148 A˚, as in the case of the DA10/
EpoR complex (non-agonist) (Figures 3E–3G). The exact EpoR
dimer separation is uncertain for the partial agonist DA330 due
to the domain swapping. Interestingly, the relative EpoR dimer
distances observed in the full and non-agonist diabody/EpoR
complexes correlate with their signaling potencies in that the full
agonist DA5 dimer is closer together, whereas the non-agonist
DA10 is further. One caveat is that the diabody molecules them-
selves are not rigid—they exhibit flexibility in the linker and hinge
angles relating the two VH/VL modules, raising the question of
whether we captured one of a range of dimer angles that could
be enforced by crystal lattice contacts.We performed conforma-
tional sampling studies exploring the relationship between the
EpoR separation distance as a function of the diabody hinge
angle on the full agonist DA5 and the non-signaling DA10 (Fig-
ure S6 and Movies S1 and S2). The results of these studies
show that the thermodynamically permitted variation in diabody
hinge angles appears to occupy a few energy minima, leading to
only a small range of alternative conformations (i.e., distances)
around that seen in the crystal structures (Figure S6 and Movies
S1 and S2). The sampling of these alternative conformations has
minor consequences on the inter-EpoR distances.
It is important to emphasize that, because we observe differ-
ences in both the EpoR/diabody docking angles (Figures 3A
and 3B) and the distances between EpoRC termini in the dimeric
complexes, we cannot say whether distance or geometry/
topology, or a combination of both factors, is responsible for
the differences in signaling between the complexes. However,
that the differences in signaling amplitude correlate with alterna-
tive overall extracellular dimer topologies appears quite clear.
Such large differences in extracellular architecture would likely
influence the relative orientation and proximity of the two JAKs
associated with the membrane proximal intracellular domains
of the receptors and impact their subsequent phosphorylation
profiles (Figure 5A).
Comparable Spatiotemporal Dynamics of EpoR
Assembly by EPO and Diabodies
An important mechanistic question is whether the diabody/EpoR
complexes on the cell surface are indeed homodimers or higher-
order species due to clustering of preformed EpoR dimers,
which has been reported previously (Constantinescu et al.,
2001; Livnah et al., 1999). To explore the ability of the diabodies
to dimerize EpoR in the plasma membrane, we probed the as-
sembly and diffusion dynamics of signaling complexes by
dual-color single-molecule imaging. For this purpose, EpoR
fused to an N-terminal monomeric EGFP (mEGFP) was ex-
pressed in HeLa cells and labeled by addition of anti-GFP nano-
bodies (Rothbauer et al., 2008), which were site-specifically con-
jugated with DY647 and ATTO Rho11, respectively (Figure 4A).
We labeled the receptors extracellularly so as not to introduce
fusion proteins to the intracellular regions that may result in arti-
factual dimerization behavior. Efficient dual-color labeling suit-
able for long-term observation of individual EpoR was achieved
with typical densities of 0.3 molecules/mm2 in both channels,
which was exploited for co-localization and co-tracking analysis.
In the absence of an agonist, independent diffusion of EpoRmol-
ecules could be observed (Movie S3) with no significant single-
molecule co-localization beyond the statistical background
(Figure 4B). Single-molecule co-tracking analysis corroborated
the absence of pre-dimerized EpoR at the plasma membrane
(Figures 4C and 4D). Upon addition of EPO, dimerization of
EpoR was detectable by both co-localization and co-trackinganalysis (Movie S3 and Figures 4B–4D). Individual receptor di-
mers could be tracked (Movie S3), and a clear decrease in their
mobility compared to EpoR in absence of ligand was identified
(Figure 4E). Stimulation of EpoR endocytosis in presence of
EPO was observed, which was accompanied by an increased
fraction of immobile EpoR molecules in presence of EPO. The
stoichiometry within individual complexes was analyzed by pho-
tobleaching at elevated laser power. Single-step photobleaching
confirmed the formation of EpoR dimers in the plasma mem-
brane (Movie S4 and Figure 4F). Upon labeling the mEGFP-
EpoR only with ATTO-Rho11, two-step bleaching could be
observed only in presence of EPO (Movie S5). For all diabodies,
very similar levels of receptor dimerization were obtained (Movie
S3 and Figure 4D). A slightly increased dimerization level
compared to EPO was observed, which may be due to the sym-
metric binding affinities of diabodies to both EpoR subunits
compared to the asymmetric receptor dimer assembly observed
for EPO. Importantly, the diffusion properties of receptor dimers
assembled by the diabodies were comparable to EPO, as shown
for DA5 in Figure 4E, confirming a comparable mode of receptor
dimerization by diabodies compared to EPO. Moreover, 1:1 re-
ceptor dimers recruited by the diabodies is observed by sin-
gle-step photobleaching (Figure 4F). Thus, although we do not
rule out any role of EpoR pre-association in the observed
signaling effects, our microscopy data indicate that the diabod-
ies are not simply clustering quiescent EpoR dimers into higher-
order assemblies.
EpoR Diabodies Inhibit Erythroid Colony Formation in
JAK2V617F-Positive Patients
Several mutations in JAKs are known to cause immune disorders
and cancer by rendering activation ligand independent (Ga¨bler
et al., 2013; James et al., 2005). We asked whether the large
EpoR distances and different binding geometries induced by
the diabodies could modulate the activity of these kinase mu-
tants in an extracellular ligand-dependent manner by separating
the two JAKs at distances where they could not undergo trans-
activation. The JAK2V617F mutant is the best-described
example of an oncogenic JAK mutation, causing the develop-
ment of hematological disorders such as polycythemia vera
(PV) and other myeloproliferative (MPN) neoplasms (Baxter
et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine
et al., 2005). At physiologic expression levels, JAK2V617F-pos-
itive cells require EpoR to proliferate in a ligand-independent
manner (Lu et al., 2008). Stimulation of Ba/F3 cells expressing
the murine EpoR and the JAK2V617F mutant with EPO or DA5
did not significantly affect the basal phosphorylation of STAT5,
Akt, and Erk in these cells (Figures 5B and 5C). However, stimu-
lation of these cells with DA10, DA307, and DA330 decreased
the STAT5, Akt, and Erk phosphorylation in a time-dependent
manner (Figures 5B and 5C). This decrease in signal activation
induced by DA10, DA307, and DA330 was not the result of
EpoR surface depletion. Only the full agonists, EPO and DA5,
led to a significant decrease in the levels of EpoR on the surface
(Figure 5D). The decrease in the JAK2V617F-induced basal
signaling activation promoted by the diabodies was followed
by a reduction in the proliferation rate of Ba/F3 cells expressing
the mutated JAK2 (Figure 5E), suggesting that oncogenic JAKCell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc. 1201
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F
B Figure 4. Diabodies Dimerize EpoR at the
Surface of Living Cells
(A) Cell-surface labeling of EpoR using dye-labeled
anti-GFP nanobodies.
(B) Relative co-localization of RHO11EpoR and
DY647EpoR in absence and presence of ligand. As
a negative control, co-localization of maltose
binding protein fused to an indifferent trans-
membrane domain is shown. Data (mean ± max/
min) are shown.
(C) Trajectories (150 frames, 4.8 s) of individual
Rho11-labeled (red) and DY647-labeled EpoR
(blue) and co-trajectories (magenta) for un-
stimulated cells, as well as after stimulation with
EPO (5 nM) and DA5 (250 nM).
(D) Relative amount of co-trajectories for un-
stimulated EPOR and after stimulation with EPO
and diabodies (DA5, DA330, and DA10). Data
(mean ± max/min) are shown.
(E) Diffusion properties of EpoR represented as
trajectory step-length distribution (time lapse:
160 ms) for unstimulated cells and after dimeriza-
tion with EPO or DA5. The curves correspond to
fitted data from>10 cells (1,500 trajectories each).
(F) Diabody-induced dimerization of EpoR demon-
strated by dual-step bleaching analysis. Top: a
pseudo-3D kymograph illustrating dual-
color single-step bleaching for an individual DA5-
induced EpoR co-trajectory. Bottom left: the
corresponding pixel-intensity profiles are shown for
both acquisition channels. Bottom right: the frac-
tion of signals within co-trajectories that decay
within a single step versus multiple steps. Com-
parison for complexes obtainedwith EPO (from 154
co-trajectories) and DA5 (from 186 co-trajectories).mutant activities can be modulated in an extracellular ligand-
dependent manner.
The Ba/F3 cells used here are a transformed cell line engi-
neered to overexpress EpoR and JAK2V617F, which led to
transformation and to autonomous growth, so we also per-
formed erythroid colony formation assays in primary cells
from human JAK2V617F-positive patients. CD34+ hemato-
poietic stem cells and progenitors (HSPC) from heterozygous
JAK2V617F-positive patients were isolated and stimulated with
the indicated diabodies ± EPO, and their ability to form erythroid
colonies was assayed. In the absence of diabodies, JAK2V617F-
positive CD34+ cells gave rise to erythroid colonies, which were
further increased in numbers in the presence of EPO in themedia
(Figure 6A). Stimulation with a non-specific negative control dia-
body did not significantly alter the number of erythroid (EpoR-
dependent) or myeloid colonies (EpoR independent) (Figures
6A and 6B), ruling out possible toxic side effects induced by1202 Cell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc.diabodies. Stimulation of JAK2V617F-
positive CD34+ cells with the agonistic
diabody DA5 led to a specific increase in
the number of erythroid colonies (Figures
6A and 6C) without significantly altering
the number of myeloid colonies (Fig-
ure 6B). On the other hand, stimulationwith DA330 and DA10 led to a potent and specific decrease in
the number of erythroid colonies (Figures 6A–6C). We note that
DA330, which is a partial agonist of normal JAK2 signaling, limits
but does not prevent signaling in JAK2V617F cells, giving the
appearance of a structural ‘‘governor’’ controlling signaling
output. All of the colonies analyzed in the study harbored the
JAK2V617F mutation as determined by single-colony genotyp-
ing (Figure 6D). The diabody with the largest intersubunit
distance, DA10, inhibited colony formation the strongest,
comparably to the JAK1/2 inhibitor Ruxolitinib, which is
approved and standard of care for JAK2V617F-positive MPN
(Verstovsek et al., 2010) (Figure 6A). DA10 also decreased the
number of erythroid colonies from homozygous JAK2V617F-
positive patients (Dupont et al., 2007) (Figures 6E and 6F),
suggesting that the binding topology imposed by this diabody
dominates over the influence of the mutated JAK2 expressed
in the cell. Overall, these results show that extracellular ligands
AB
D E
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Figure 5. DA10 and DA330 Inhibit
JAK2V617F Constitutive Activity
(A) Model depicting the mechanism by which the
diabodies affect signaling activation potencies.
The large dimer intersubunit distances exhibited
by the diabodies may alter the position of JAK2
upon ligand binding, decreasing its ability to
transactivate each other and start downstream
signaling amplification.
(B) Kinetics of pSTAT5 in Ba/F3 cells expressing
the JAK2V617F mutant after stimulation with EPO
or the four diabodies. DA10, DA307, and DA330
induce a decrease on the basal pSTAT5 levels in
a time-dependent manner. Data (mean ± SD) are
from two independent experiments.
(C) pSTAT5, pErk, and pAkt levels induced by 1 mM
of the four diabodies in Ba/F3 cells expressing the
JAK2V617F mutant after 3 hr of stimulation.
(D) EpoR surface levels after 1 hr stimulation with
EPO or the four diabodies.
(E) Proliferation of Ba/F3 cells expressing JAK2
WT or JAK2V617F in response to 1 mM of each
of the four diabodies after 5 days of stimulation.
Data (mean ± SD) are from three independent
experiments.that enforce large receptor dimer separation and different bind-
ing geometries can counteract intracellular oncogenic ligand-
independent receptor activation, presumably by exceeding
the accessible distance that the JAK2 kinase domain can
extend to transphosphorylate the opposing JAK2 and receptor
(Figure 5A).
DISCUSSION
Single-pass type I and type II transmembrane receptors that
contain ligand-binding ECDs constitute a major percentage of
all signaling receptors in the mammalian genome and include
cytokine (JAK/STAT) receptors (Spangler et al., 2014), tyrosine
kinase (RTK) receptors (e.g., EGF-R, Insulin-R, etc.) (Lemmon
and Schlessinger, 2010), and many others. In most cases, these
receptors signal in response to ligand engagement as homo- or
heterodimeric units (Klemm et al., 1998; Stroud andWells, 2004).Cell 160, 1196–1208For this class of receptors, ligand binding
ECDs are structurally autonomous and
are separated from the intracellular
signaling modules (e.g., Kinase domains)
through juxtamembrane linkers and a
TM helix. Thus, the intracellular domains
(ICDs) presumably sense ligand binding
through spatial perturbations of receptor
orientation and proximity that are relayed
as conformational changes through
the membrane (Ottemann et al., 1999).
However, it has been unclear to what
extent extracellular ligands can influence
signaling through dimeric receptors by
enforcing ECD orientational differences.
In contrast, for GPCRs, although the roleof dimerization remains to be determined, it is well established
that ligand binding within the TM helices induces conformational
changeswithin the plane of themembrane. Evenminor structural
differences in the relative orientations of GPCR TM helices
induced by ligands are conveyed as differential signaling (e.g.,
biased signaling, inverse and partial agonism) (Venkatakrishnan
et al., 2013). This property of GPCRs has been exploited by the
pharmaceutical industry for small-molecule drug develop-
ment. Here, we asked whether ligand-induced orientational
(i.e., ‘‘shape’’) changes of receptor dimer geometry could serve
a conceptually and functionally analogous role to the diverse
types of conformational changes induced by GPCR ligands
that result in differential signaling.
Although there exists a vast literature showing that dimeric
receptor signaling strength is determined by extracellular
parameters such as ligand affinity and complex half-life on the
cell surface (Harwerth et al., 1992; Riese, 2011), the role of, March 12, 2015 ª2015 Elsevier Inc. 1203
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Colony Formation in JAK2V617F-Positive
Patient Samples
(A) Number of erythroid BFU-E (EpoR-dependent)
colonies in heterozygous JAK2V617F positive
myeloproliferative neoplasm patient samples after
stimulation with the indicated ligands. Data (mean
± SD) are from three different donors.
(B) Number of myeloid colonies in heterozygous
JAK2V617F-positive myeloproliferative neoplasm
patient samples after stimulation with the indicated
ligands.
(C) Overview pictures highlight EPO-independent
BFU-E colonies (no drug and DA5), which are
significantly diminished with DA330 and DA10
treatment. *p < 0.05; **p < 0.01; ***p < 0.001; paired
Student’s t test was used to determine significant
changes.
(D) The genotype of 109 erythroid colonies derived
from sorted CD34+ cells derived from PMF cases
was determined by multiplexed custom TaqMan
SNP assay for JAK2V617F and JAK2 wild-type.
Each colony is represented by a single dot in the
graph and colored according to different treatment
regimens. Gray dots represent colonies derived
from conditions without treatment or treatment
with an agonist (dark gray with EPO, light gray
without EPO), orange and green dots represent
few residual colonies treated with DA330, and blue
and red dots very rare residual colonies treated
with DA10.
(E) Number of erythroid colonies (burst-forming
units-erythroid [BFU] or endogenous erythroid
colonies [EEC]) and myeloid colonies (EpoR-in-
dependent) in a polycythemia vera (PV) (top) and
primary myelofibrosis (PMF) patient (bottom panel)
homozygous for JAK2V617F. SI: SCF + IL-3; SIE:
SCF +IL-3 + EPO. Data (mean ± SD) are from three
different donors.
(F) Morphology of EEC colonies after treatment
with the indicated conditions is shown.orientation-specific effects has remained speculative (Ballinger
and Wells, 1998; Syed et al., 1998; Wells and de Vos, 1993).
Studies using mutated, chimeric, or genetically modified recep-
tors have pointed to the importance of the extracellular domain
structure in mediating signaling output (Barclay et al., 2010; Liu
et al., 2009; Millot et al., 2004; Rowlinson et al., 2008; Seubert
et al., 2003; Staerk et al., 2011). Nevertheless, for this parameter
to be exploited in a manner that could be useful therapeutically,
surrogate ligands with the capacity to induce alternative
signaling outputs through naturally, non-mutated receptors on
human cells are required. We used diabodies because they
would presumably induce large-scale alterations in dimer geom-
etry and have been previously shown to have the capacity to act
as agonists of c-MPL (Nakano et al., 2009). Although antibodies
have been shown to elicit diverse functional and signaling out-1204 Cell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc.puts through cytokine receptors (Zhang
et al., 2012a; Kai et al., 2008), they are
elusive structural targets due to their
segmental flexibility. Diabodies havemore constrained structures than antibodies (Perisic et al.,
1994), which allowed us to capture the receptor-diabody
signaling complexes crystallographically.
Our results indicate that cytokine receptor dimer architectural
and spacing constraints compatible with signaling are liberal but
there exist limits at which signaling is impacted. This is consis-
tent with the diverse range of dimeric ligand-receptor geometries
seen in agonistic cytokine-receptor complex structures (Span-
gler et al., 2014; Wang et al., 2009). Consequently, we find that
large-scale re-orientations of receptor dimer topology are
required to qualitatively and quantitatively modulate signaling
output. We propose that this strategy is potentially applicable
to other dimeric receptor systems, such as RTKs, where the
role of ligand is to bind to the ECDs, dimerize, and/or re-orient
receptors.
The broader implications of our results are that signaling
patterns delivered by endogenous ligands only constitute one
of many possible signaling patterns that can be elicited through
a dimeric receptor system. By using surrogate or engineered li-
gands to re-orient receptor dimer topology, a given dimeric
receptor can be induced to deliver a wide range of signals of
different amplitudes and pathway specificities. Cytokine recep-
tor dimers have the potential to be modulated as rheostats to
control signaling output, similar to partial and biased GPCR
agonists. Given that many endogenous cytokines and growth
factors have adverse effects as therapeutic agonists, our results
portend the possibility of dimer re-orientation as a strategy to
‘‘tune’’ signaling output to minimize toxicity, maximize efficacy,
or elicit specific functional outcomes.
The precisemolecular mechanisms throughwhich the diabod-
ies described here alter intracellular signaling by remodeling
dimer geometry remain unclear, but the signal tuning effects
are clearly the result of extracellular receptor dimer proximity
(distance) and geometry (orientation) effects. Our single-mole-
cule fluorescence tracking shows that the assembled signaling
complexes are not due to higher-order assemblies that could
have resulted from diabody-induced clustering of preformed
EpoR receptor dimers (Constantinescu et al., 2001). Even if re-
ceptor clustering were occurring to some degree, which we do
not rule out, the diabodies still exert a powerful modulatory effect
on signaling through repositioning receptor topology whether or
not these are monovalent or polyvalent cell-surface complexes.
This strategy does not rely on a particular valency of the signaling
complexes. For example, our results can be reconciled with a
recent mechanistic study of cytokine receptor activation (Brooks
et al., 2014). Growth hormone was shown to activate its receptor
(GH-R) by rotating the ECD subunits of a pre-associated but
inactive GH-R dimer, resulting in separation of the Box 1 recep-
tor ICD motifs and removal of the JAK2 pseudokinase inhibitory
domain, which collectively result in productive JAK2 kinase
domain positioning for receptor activation. Diabodies could
presumably disrupt a quiescent cytokine receptor dimer to
form an activated dimer topology through a related ‘‘separation’’
mechanism that relieves JAK2 inhibition. For the agonist DA5,
the outcome of this separation would be placement of the JAK
kinase domains into productive apposition but one that is topo-
logically distinct from that induced by the natural cytokine. In the
case of DA10, the kinase domains of JAK2 are separated such
that they are not in proper position to trans-phosphorylate. We
contend that such a JAK activation mechanism could still be
operative in the context of non-native dimer architectures.
The surprisingly large EpoR dimer separation distances
imposed by the agonistic diabodies may be rationalized by the
fact that the intracellular, receptor-associated JAKs are long
molecules that exists as a dynamic ensemble of extended and
compact conformations, which could span >100A˚ distances be-
tween receptors in a dimer (Lupardus et al., 2011). Given that the
kinase domain of JAK resides at its C terminus, which is most
distal to the receptor bound by the JAK FERM domain, it is likely
sensitive to positioning relative to its substrates that it trans-
phosphorylates. Changes in the relative positioning of the kinase
domain to its substrates could influence the efficiency and pat-
terns of phosphorylation through steric effects imposed byextracellular dimer geometry. By manipulating the dimer geom-
etry, as seen with the non-signaling diabody DA10, such an
approach can achieve complete shutoff of constitutively active
signaling pathways (JAK2V617F) from the outside of the cell.
This is conceptually distinct from Ankyrin repeat antagonists
to ErbB2 that were shown to prevent activation of wild-type
ErbB2 by distorting the receptors such that they cannot form
signaling-competent dimers (Jost et al., 2013). Here, the role of
DA10 is to dimerize EpoR yet terminate ligand-independent
signaling, possibly through enforcing a large dimer separation
distance. This strategy is applicable to diseases mediated by
mutated, constitutively active receptors (Bivona et al., 2011; Pik-
man et al., 2006; Rebouissou et al., 2009; Zenatti et al., 2011) and
could offer the advantage of specificity and reduced toxicity
versus broadly neutralizing kinase inhibitors.
Diabodies are a convenient surrogate ligand because they can
be created from existingmonoclonal antibody sequences, which
exist to most human cell-surface receptors. However, dimer re-
orientation could be achieved by many different types of engi-
neered scaffolds. A range of altered dimerization geometries
could be screened with different dimerizing scaffolds for those
that induced a particular signaling profile or functional property.
In principle, targeting receptor ECD dimer orientation as a new
structure-activity parameter for drug discovery for many type I
or type II cell-surface receptors is feasible.
EXPERIMENTAL PROCEDURES
Further details for production, characterization, and crystallization of diabod-
ies; signaling and functional characterization; in vivo imaging of surface
DA-EpoR complex formation; and isolation and treatment of JAK2V617F-
positive human samples can be found online in the Extended Experimental
Procedures.
Structure Determination and Refinement
All crystallographic data were collected at the Stanford Synchroton Radiation
Lightsource (Stanford) beamlines 12-2. Data were indexed, integrated and
scaled using XDS or HKL2000 program suits (Kabsch, 2010; Otwinowski
et al., 1997). The three DA-EpoR crystal structures were solved by molecular
replacement with the program PHASER (McCoy, 2007) and refined with
PHENIX and COOT.
Primity Bio Pathway Phenotyping
UT-7-EpoR cells were starved overnight; stimulated with saturated concentra-
tions of EPO and the indicated diabodies for 15, 60, and 120 min; and fixed
with 1% PFA for 10 min at room temperature. The fixed cells were prepared
for antibody staining according to standard protocols (Krutzik and Nolan,
2003). Briefly, the fixed cells were permeabilized in 90% methanol for
15 min. The cells were stained with a panel of antibodies specific to the
markers indicated (Primity Bio Pathway Phenotyping service and Table S1)
and analyzed on an LSRII flow cytometer (Becton Dickinson). The Log2 Ratio
of the median fluorescence intensities (MFI) of the stimulated samples divided
by the unstimulated control samples were calculated as a measure of
response.
Single-Molecule Tracking, Co-localization, and Co-tracking
Analyses
Single-molecule localization and single-molecule tracking were carried out us-
ing themultiple-target tracing (MTT) algorithm (Serge´ et al., 2008) as described
previously (You et al., 2010). Step-length histograms were obtained from
single-molecule trajectories and fitted by a two fraction mixture model of
Brownian diffusion. Average diffusion constants were determined from the
slope (2–10 steps) of the mean square displacement versus time lapseCell 160, 1196–1208, March 12, 2015 ª2015 Elsevier Inc. 1205
diagrams. Immobile molecules were identified by the density-based spatial
clustering of applications with noise (DBSCAN) (Sander et al., 1998) algorithm
as described recently (Roder et al., 2014). For comparing diffusion properties
and for co-tracking analysis, immobile particles were excluded from the data
set. Individualmolecules detected in the both spectral channelswere regarded
as co-localized if a particle was detected in both channels of a single frame
within a distance threshold of 100 nm radius.
HSC and Progenitor-Derived Colony Genotyping Assay
CD34+ cells were sorted from human JAK2V617F homo- and heterozygous
myeloproliferative samples. CD34+ cells were plated in methylcellulose with
andwithout erythropoietin (MethoCult H4434andH4535; STEMCELL Technol-
ogies). Colony formation was assessed after 14 days in culture by microscopy
and scored on the basis of morphology. JAK2V617F and JAK2 WT TaqMan
SNP Genotyping Assay (Applied Biosystems) was designed as published
recently (Levine et al., 2006), and details are available upon request. The geno-
type of each colony was determined by Custom TaqMan SNP Genotyping
Assay (Applied Biosystems) according to the manufacturer’s specification.
ACCESSION NUMBERS
The Protein Data Bank (PDB) accession numbers for the three DA/EpoR
complex structures reported in this paper are 4Y5V (DA5-EpoR), 4Y5X
(DA10-EpoR), and 4Y5Y (DA330-EpoR). RNA-seq data can be accessed via
National Center for Biotechnology Information (NCBI) BioProject under the
accession number PRJNA275804.
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